- Home
- WHF vs CCCC Comparison
WHF vs CCCC Comparison
Compare WHF & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- CCCC
- Stock Information
- Founded
- WHF 2011
- CCCC 2015
- Country
- WHF United States
- CCCC United States
- Employees
- WHF N/A
- CCCC N/A
- Industry
- WHF Finance Companies
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- CCCC Health Care
- Exchange
- WHF Nasdaq
- CCCC Nasdaq
- Market Cap
- WHF 207.1M
- CCCC 175.1M
- IPO Year
- WHF 2012
- CCCC 2020
- Fundamental
- Price
- WHF $8.83
- CCCC $3.41
- Analyst Decision
- WHF Hold
- CCCC Strong Buy
- Analyst Count
- WHF 4
- CCCC 3
- Target Price
- WHF $10.00
- CCCC $8.67
- AVG Volume (30 Days)
- WHF 68.1K
- CCCC 1.3M
- Earning Date
- WHF 11-06-2025
- CCCC 10-30-2025
- Dividend Yield
- WHF 20.25%
- CCCC N/A
- EPS Growth
- WHF N/A
- CCCC N/A
- EPS
- WHF 0.15
- CCCC N/A
- Revenue
- WHF $81,499,000.00
- CCCC $34,240,000.00
- Revenue This Year
- WHF N/A
- CCCC N/A
- Revenue Next Year
- WHF N/A
- CCCC N/A
- P/E Ratio
- WHF $57.60
- CCCC N/A
- Revenue Growth
- WHF N/A
- CCCC 16.55
- 52 Week Low
- WHF $8.36
- CCCC $1.09
- 52 Week High
- WHF $12.42
- CCCC $7.14
- Technical
- Relative Strength Index (RSI)
- WHF 61.60
- CCCC 70.84
- Support Level
- WHF $8.70
- CCCC $2.58
- Resistance Level
- WHF $8.86
- CCCC $3.65
- Average True Range (ATR)
- WHF 0.10
- CCCC 0.23
- MACD
- WHF 0.03
- CCCC 0.06
- Stochastic Oscillator
- WHF 72.55
- CCCC 81.82
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.